CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Solutions for surgical side effects

Drug to reduce macular oedema risk after cataract surgery approved

Eye drops

The European Medicines Agency has approved a new medication to reduce the chances that diabetic patients undergoing cataract surgery will experience macular oedema.

The new drug, Novartis Pharmaceutical’s Nevanac 3mg eye drops, was granted the approval on the back of two studies to be presented at the European Society of Cataract & Refractive Surgeons Annual Congress this week (10–14 September, Copenhagen).

In contrast to other options, the Nevanac eye drops only need to be used once a day to reduce the risk of macular oedema, Novartis Pharmaceuticals global programme head, Eric Carlson told OT.

“This really reduces the treatment burden,” he added.

Macular oedema, which can result in irreversible vision loss, is the most common cause of sight loss following the surgical procedure.

With growing numbers of diabetic patients, more options to reduce the chances of macular oedema will ensure patients’ vision is protected, Mr Carlson highlighted.

“They can undergo a procedure to restore or improve vision that can cause a condition that reduces vision in the end,” he emphasised.

Image credit: Lynn Greyling